Determination of common urine substances as an assay for improving prostate carcinoma diagnostics

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1846-1854

  Heger, Zbynek ^a   Cernei, Natalia ^a,b   Gumulec, Jaromir ^b,c   Masarik, Michal ^b,c   Eckschlager, Tomas ^d   Hrabec, Roman ^e   Zitka, Ondrej ^a,b   Adam, Vojtech ^a,b   Kizek, Rene ^a,b  

^a MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^b BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^e ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Immunoenzymometric assay; Ion exchange liquid chromatography; Proline; PSA; Sarcosine; Spectrophotometry

Indexed keywords

AMINO ACID; PROLINE; PROSTATE SPECIFIC ANTIGEN; SARCOSINE; TUMOR MARKER; URIC ACID;

ADULT; AGED; AMINO ACID METABOLISM; AMINO ACID URINE LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CHEMICAL PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; HUMAN; IMMUNOENZYMOMETRIC ASSAY; MALE; METABOLITE; PRIORITY JOURNAL; PROLINE URINE LEVEL; PROSTATE CARCINOMA; PROSTATE SPECIFIC ANTIGEN URINE LEVEL; PROTEIN METHYLATION; SARCOSINE URINE LEVEL; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY; URIC ACID URINE LEVEL; URINALYSIS; URINE LEVEL; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CHROMATOGRAPHY, LIQUID; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROLINE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SARCOSINE; TUMOR MARKERS, BIOLOGICAL; URIC ACID;

EID: 84908129272     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3054     Document Type: Article

References (59)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Ding ZH, Wu CJ, Chu GC, et al: SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470: 269-273, 2011.
3. Boyle P and Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488, 2005.
4. Armstrong AJ, Eisenberger MA, Halabi S, et al: Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 61: 549-559, 2012.
5. Prensner JR, Rubin MA, Wei JT and Chinnaiyan AM: Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 4: 1-12, 2012.
6. Lattanzi J, McNeely S, Hanlon A, Das I, Schultheiss TE and Hanks GE: Daily CT localization for correcting portal errors in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 41: 1079-1086, 1998.
7. van Vugt HA, Roobol MJ, Busstra M, et al: Compliance with biopsy recommendations of a prostate cancer risk calculator. BJU Int 109: 1480-1488, 2012.
8. Schoder H and Larson SM: Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 34: 274-292, 2004.
9. Fukushima K, Satoh T, Baba S and Yamashita K: α 1,2-Fucosylated and β-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology 20: 452-460, 2010.
10. Page ST, Hirano L, Gilchriest J, et al: Dutasteride reduces prostate size and prostate-specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol 186: 191-197, 2011.
11. Zitka O, Cernei N, Heger Z, et al: Microfluidic chip coupled with modified paramagnetic particles for sarcosine isolation in urine. Electrophoresis 34: 2639-2647, 2013.
12. Berger MF, Lawrence MS, Demichelis F, et al: The genomic complexity of primary human prostate cancer. Nature 470: 214-220, 2011.
13. Cao DL, Ye DW, Zhang HL, Zhu Y, Wang YX and Yao XD: A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate 71: 700-710, 2011.
14. Rigau M, Morote J, Mir MC, et al: PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate 70: 1760-1767, 2010.
15. Crawford ED, Rove KO, Trabulsi EJ, et al: Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol 188: 1726-1731, 2012.
16. Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z and Bouchal J: Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis 13: 12-19, 2010.
17. Pin E, Fredolini C and Petricoin EF: The role of proteomics in prostate cancer research: biomarker discovery and validation. Clin Biochem 46: 524-538, 2013.
18. Vesprini D, Liu S and Nam R: Predicting high risk disease using serum and DNA biomarkers. Curr Opin Urol 23: 252-260, 2013.
19. Sreekumar A, Poisson LM, Rajendiran TM, et al: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914, 2009.
20. Cavaliere B, Macchione B, Monteleone M, Naccarato A, Sindona G and Tagarelli A: Sarcosine as a marker in prostate cancer progression: a rapid and simple method for its quantification in human urine by solid-phase microextraction-gas chromatography-triple quadrupole mass spectrometry. Anal Bioanal Chem 400: 2903-2912, 2011.
21. Petersen LF, Brockton NT, Bakkar A, et al: Elevated physiological levels of folic acid can increase in vitro growth and invasiveness of prostate cancer cells. BJU Int 109: 788-795, 2012.
22. Lucarelli G, Fanelli M, Larocca AMV, et al: Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate 72: 1611-1621, 2012.
23. Cernei N, Heger Z, Gumulec J, et al: Sarcosine as a potential prostate cancer biomarker: a review. Int J Mol Sci 14: 13893-13908, 2013.
24. Chen JL, Tang HQ, Hu JD, Fan J, Hong J and Gu JZ: Metabolomics of gastric cancer metastasis detected by gas chromatography and mass spectrometry. World J Gastroenterol 16: 5874-5880, 2010.
25. Hirayama A, Kami K, Sugimoto M, et al: Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 69: 4918-4925, 2009.
26. Slupsky CM, Steed H, Wells TH, et al: Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 16: 5835-5841, 2010.
27. Kim K, Taylor SL, Ganti S, Guo LN, Osier MV and Weiss RH: Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS 15: 293-303, 2011.
28. Phang JM: The regulatory functions of proline and pyrroline-5-carboxylic acid. Curr Top Cell Regul 25: 91-132, 1985.
29. Pandhare J, Cooper SK and Phang JM: Proline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-activated receptor γ-dependent and -independent mechanisms. J Biol Chem 281: 2044-2052, 2006.
30. Pandhare J, Donald SP, Cooper SK and Phang JM: Regulation and function of proline oxidase under nutrient stress. J Cell Biochem 107: 759-768, 2009.
31. Polyak K, Xia Y, Zweier K, Kinzler W and Vogelstein B: A model for p53-induced apoptosis. Nature 389: 300-305, 1997.
32. Donald SP, Sun XY, Hu CAA, et al: Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species. Cancer Res 61: 1810-1815, 2001.
33. Liu Y, Borchert GL, Surazynski A, Hu CA and Phang JM: Proline oxidase activates both intrinsic and extrinsic pathways for apoptosis: the role of ROS/superoxides, NFAT and MEK/ERK signaling. Oncogene 25: 5640-5647, 2006.
34. Liu W, Le A, Hancock C, et al: Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci USA 109: 8983-8988, 2012.
35. Phang JM and Liu W: Proline metabolism and cancer. Front Biosci 17: 1835-1845, 2012.
36. Liu W, Zabirnyk O, Wang H, et al: miR-23b* targets proline oxidase, a novel tumor suppressor protein in renal cancer. Oncogene 29: 4914-4924, 2010.
37. Liu Y, Borchert GL, Surazynski A and Phang JM: Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers. Oncogene 27: 6729-6737, 2008.
38. Ianni M, Porcellini E, Carbone I, et al: Genetic factors regulating inflammation and DNA methylation associated with prostate cancer. Prostate Cancer Prostatic Dis 16: 56-60, 2013.
39. Luka Z, Cerone R, Phillips JA, Mudd SH and Wagner C: Mutations in human glycine N-methyltransferase give insights into its role in methionine metabolism. Hum Genet 110: 68-74, 2002.
40. Pelzer AE, Volgger H, Bektic J, et al: The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels. BJU Int 96: 995-998, 2005.
41. Sirovich BE, Schwartz LM and Woloshin S: Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 289: 1414-1420, 2003.
42. Seo HS and Lee NK: Predictors of PSA screening among men over 40 years of age who had ever heard about PSA. Korean J Urol 51: 391-397, 2010.
43. Demers LM, Costa L, Chinchilli VM, Gaydos L, Curley E and Lipton A: Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 41: 1489-1494, 1995.
44. Catalona WJ, Partin AW, Slawin KM, et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279: 1542-1547, 1998.
45. Lapi F, Azoulay L, Niazi T, Yin H, Benayoun S and Suissa S: Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA 310: 289-296, 2013.
46. Nariculam J, Murphy DG, Jenner C, et al: Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer. Br J Radiol 82: 571-576, 2009.
47. Panis C, Victorino VJ, Herrera ACSA, et al: Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res Treat 133: 881-888, 2012.
48. Xu XL, Rao GS, Groh V, et al: Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer 11: 194, 2011.
49. Burgaz S, Torun M, Yardim S, Sargin H, Orman MN and Ozdamar NY: Serum carotenoids and uric acid levels in relation to cancer. J Clin Pharm Ther 21: 331-336, 1996.
50. Kolonel LN, Yoshizawa C, Nomura AMY and Stemmermann GN: Relationship of serum uric-acid to cancer occurrence in a prospective male cohort. Cancer Epidemiol Biomarkers Prev 3: 225-228, 1994.
51. Koyner JL, Vaidya VS, Bennett MR, et al: Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol 5: 2154-2165, 2010.
52. Chen CH and Lin MS: A novel structural specific creatinine sensing scheme for the determination of the urine creatinine. Biosens Bioelectron 31: 90-94, 2012.
53. Elsberger B, Lankston L, McMillan DC, Underwood MA and Edwards J: Presence of tumoural C-reactive protein correlates with progressive prostate cancer. Prostate Cancer Prostatic Dis 14: 122-128, 2011.
54. Grases F, Costa-Bauza A and Prieto RM: Renal lithiasis and nutrition. Nutr J 5: 1-7, 2006.
55. Montrose DC, Zhou XK, Kopelovich L, et al: Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev Res 5: 1358-1367, 2012.
56. Green T, Chen XF, Ryan S, Asch AS and Ruiz-Echevarria MJ: TMEFF2 and SARDH cooperate to modulate one-carbon metabolism and invasion of prostate cancer cells. Prostate 73: 1561-1575, 2013.
57. Khan AP, Rajendiran TM, Ateeq B, et al: The role of sarcosine metabolism in prostate cancer progression. Neoplasia 15: 491-501, 2013.
58. Isaacs WB: Inherited susceptibility for aggressive prostate cancer. Asian J Androl 14: 415-418, 2012.
59. Powell IJ, Bock CH, Ruterbusch JJ and Sakr W: Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 183: 1792-1796, 2010.